PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

PatentVest has unveiled its latest report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” highlighting an escalating competition in the oral GLP-1 (glucagon-like peptide-1) drug market. As injectable GLP-1 medications have burgeoned into a $71 billion industry, they have reached only a fraction of potential patients. In response, 50 oral small-molecule programs are currently in the race to provide an alternative, aiming to capture the 95% of eligible patients still untreated.

Key clinical trials indicate that leading oral programs are achieving weight-loss results that typically fall within the 12–16% range, underscoring a significant convergence in efficacy among competitors. Nonetheless, long-term market success is anticipated to hinge not solely on clinical outcomes but also on the robustness of each program's patent portfolio. The report meticulously reviews over 1,200 patent documents linked to 26 clinical-stage programs, analyzing vital elements such as composition-of-matter claims and method-of-use protections.

The financial landscape reveals that more than $47 billion related to GLP-1 deals has been secured since 2023, although the majority of oral programs remain without partnerships. With key drugs like semaglutide and tirzepatide facing patent expiration in 2031 and 2036, respectively, the strength of patent claims will crucially impact which programs can maintain market exclusivity and fend off generic competition.

Javier Chamorro, Chief Operating Officer of PatentVest, noted that as weight-loss results become similar across products, “the competitive moat shifts beneath the surface.” The report serves as the first installment in a series dedicated to assessing the structural and patent defensibility of emerging drug candidates from top pharmaceutical companies, including Eli Lilly, Novo Nordisk, and Pfizer.

The recent PatentVest report on the oral small-molecule GLP-1 patent race highlights a pivotal moment in the pharmaceutical landscape, especially as the market for injectable GLP-1 drugs reaches an impressive $71 billion. With oral alternatives set to unlock access for the remaining 95% of eligible patients, investors should closely consider the dynamics revealed by PatentVest's analysis.

As more than 50 oral programs vie for market share, understanding the competitive landscape goes beyond efficacy — patent strength and defensibility will be crucial for long-term success. The report’s examination of over 1,200 patents indicates significant variability in patent robustness among key players, with broader genus claims potentially conferring a competitive moat that can protect against generic encroachment once the patents for leading injectable products, like semaglutide, expire.

Investors should prioritize companies with strong patent portfolios and strategic IP positioning. Firms like Eli Lilly, Novo Nordisk, Pfizer, and AstraZeneca have established reputations, but ongoing patent assessment is essential as new entrants such as Structure Therapeutics begin to emerge.

Given that around $47 billion in GLP-1-related deal value has been allocated since 2023, the market shows a clear appetite for innovation. However, the report highlights that many oral candidates remain unpartnered, suggesting an opportunity for strategic acquisition or collaboration.

As we approach critical patent cliffs in the next few years, due diligence on the patent landscape will become indispensable. Monitoring the evolution of these programs and their IP strategies can provide insights and potential investment opportunities. As highlighted by Javier Chamorro, the nuances of patent claims could dictate winners and losers in this burgeoning arena, warranting careful analysis and consideration from stakeholders.